Cryoport Q3 net loss widens 56% to $10.85 million; revenue rises 14% to $50.22 million
CYRX•Cryoport’s third-quarter 2026 net loss widened 56% year over year to $10.85 million, while revenue rose 14% to $50.22 million. The company raised its full-year 2026 revenue guidance to $197 million to $199 million.
1. Quarterly results
Cryoport’s third-quarter 2026 net loss widened 56% year over year to $10.85 million. Revenue rose 14% to $50.22 million, including Life Sciences Services revenue of $28.56 million, up 18%.
2. Operations and guidance
As of September 30, 2026, Cryoport supported 788 clinical trials worldwide and 23 commercially approved cell and gene therapies. The company increased its full-year 2026 revenue guidance to a range of $197 million to $199 million.
